William (Will) Díaz litigates and counsels clients on antitrust cases, obtains Federal Trade Commission (FTC) and Department of Justice clearance on mergers, and defends clients in government investigations. Will has significant experience in the interplay between the antitrust and intellectual property laws and the issues that crossover into both areas, including standard-setting activities, patent pools, fair, reasonable and non-discriminatory (FRAND) licensing issues and patent misuse. He also has handled numerous litigations and transactions in the biotech, pharmaceutical and medtech industries.
Represented Amgen, Inc., in securing antitrust clearance for its $10.4 billion acquisition of Onyx Pharmaceuticals, Inc., which is the largest acquisition in Amgen’s history and one of the largest life sciences transactions in the industry
Represented Amgen, Inc., in defeating class action litigation involving allegations of tying and bundling (Warren General Hospital v. Amgen Inc.)
Represented Mars, Inc., in its acquisition of the Wm. Wrigley Jr. Company, a global transaction involving a number of the best known confectionary sugar brands such as Skittles® and Starburst®
Served as lead counsel for Rovi Corporation and related subsidiaries in defeating patent misuse allegations (In the Matter of Certain Products Containing Interactive Program Guide and Parent Control Technology and Netflix Inc. v. Rovi Corp., et al.)
Represented SanDisk Corporation in raising antitrust counterclaims against members of a patent pool (Audio MPEG, Inc. v. SanDisk Corporation)
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.